CCG
UTHR icon

Ceeto Capital Group’s United Therapeutics UTHR Stock Holding History

Ceeto Capital Group’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4,000
Closed -$352K – 144
2019
Q4 		$352K Hold
4,000
– – 0.23% 103
2019
Q3 		$319K Buy
+4,000
New +$322K 0.23% 105

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Ceeto Capital Group's UTHR Position: Q1 2020 in Review

Ceeto Capital Group sold out of United Therapeutics (UTHR) in Q1 2020, closing a stake of 4,000 shares — an estimated $352K sold.

Ceeto Capital Group first reported a position in UTHR in Q3 2019 and held it in 2 quarters. The position peaked at $352K in Q4 2019. 303 funds tracked by Wall St. Rank hold UTHR as of Q1 2020.

  • Ceeto Capital Group reported no remaining United Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Ceeto Capital Group sold 4,000 United Therapeutics shares in Q1 2020, an estimated $352K.
  • Ceeto Capital Group first reported a position in United Therapeutics in Q3 2019 and held it in 2 quarters.
  • Ceeto Capital Group's United Therapeutics position peaked at $352K in Q4 2019.
  • 303 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2020.

Based on Ceeto Capital Group's 13F filing for Q1 2020, filed 15 May 2020.